Ethnic Variations in Antidepressant Response

Completed · Phase 4

Conditions studied: Depression

In brief

This 11-week study aims to determine how genetic factors affect the way African Americans and Caucasians with major depression respond to antidepressant medication \[citalopram (Celexa®)\].

Key facts

Study ID

NCT00047671

Run by

National Institute of Mental Health (NIMH)

People needed

400

Starts

2002-06-01

Expected to finish

2006-11-01

Last updated by the study team

2009-08-04

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• DSM-IV criteria for Major Depression
• African-American or Caucasian ethnic background (both parents and 3 out of 4 grandparents)

You may not qualify if…

• Schizophrenia, schizophreniform disorder, schizoaffective disorder, schizotypal disorder, psychotic depression, or bipolar disorder
• Current drug abuse or history of drug abuse within the past 6 months
• Unstable medical or neurological conditions that interfere with the treatment of depression
• Allergy to citalopram
• Failure to respond to adequate citalopram drug trial (40 mg for at least 6 weeks)
• Seizure disorder
• Pregnancy
• Psychotropic medications, including antidepressants and neuroleptics
• Suicidal ideation or other safety issues
• Fluoxetine (Prozac) or MAOIs (Nardil, Parnate) in the last 2 months
• Ongoing cognitive behavioral therapy or intensive psychotherapy. General talk therapy is acceptable

Where it is running

• Cedars-Sinai Medical Center, Department of Psychiatry, Clinical Trials Unit — Los Angeles, California, United States
• UCLA/King-Drew — Los Angeles, California, United States
• Harbor-UCLA Medical Center — Torrance, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.